At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 22, 2026 at 08:00 ET
Revolution Medicines filed an 8-K announcing the planned retirement of President of R&D Steve Kelsey, effective January 4, 2027, with a transition to senior advisor starting July 1, 2026, and a contemplated board appointment. The filing also reports routine annual meeting results, including the election of two Class III directors and ratification of the auditor. No financial data or material business changes were disclosed.
- Steve Kelsey, M.D., President of Research and Development, intends to retire effective January 4, 2027.
- Dr. Kelsey will transition to Senior Advisor to the CEO from July 1, 2026, until retirement.
- The company contemplates appointing Dr. Kelsey to the Board of Directors upon his retirement, subject to Board approval.
- Annual meeting results: Alexis Borisy and Mark A. Goldsmith elected as Class III directors; PwC ratified as auditor; advisory say-on-pay approved.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access